Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Nuvectis Pharma, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/09/2023 |
8-K
| Quarterly results |
| 05/10/2023 |
8-K
| Quarterly results|
Docs:
|
"CONDENSED BALANCE SHEETS March 31, December 31, 2023 2022 Assets CURRENT ASSETS: Cash and cash equivalents $ 15,468 $ 19,993 Other current assets 740 412 TOTAL CURRENT ASSETS 16,208 20,405 TOTAL ASSETS $ 16,208 $ 20,405 Liabilities and Stockholders’ Equity CURRENT LIABILITIES Accounts payables $ 2,096 $ 2,910 Payable offering costs — 450 Accrued liabilities 156 445 Employee compensation and benefits 1,682 2,381 TOTAL CURRENT LIABILITIES 3,934 6,186 TOTAL LIABILITIES 3,934 6,186 COMMITMENTS AND CONTINGENCIES STOCKHOLDERS’ EQUITY: Common Stock, $0.00001 par value – 60,000,000 shares authorized as of March 31, 2023, and December 31, 2022, 15,886,139 and 15,190,720 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively * * Additional paid in capital 48,308 46,2..." |
|
| 11/08/2022 |
8-K
| Quarterly results |
| 08/05/2022 |
8-K
| Quarterly results|
Docs:
|
"NUVECTIS PHARMA, INC. CONDENSED BALANCE SHEETS June 30, December 31, 2022 2021 Assets CURRENT ASSETS: Cash and cash equivalents 13,572 5,742 Other current assets 666 91 TOTAL CURRENT ASSETS 14,238 5,833 Deferred offering costs — 824 TOTAL ASSETS 14,238 6,657 Liabilities, Redeemable Convertible Preferred Shares and Stockholders’ Equity Accounts payables 1,434 1,058 Payable offering costs 341 824 Accrued liabilities 790 395 Employee compensation and benefits 173 142 TOTAL CURRENT LIABILITIES 2,738 2,419 TOTAL LIABILITIES 2,738 2,419 COMMITMENTS AND CONTINGENCIES, see Note 3 REDEEMABLE CONVERTIBLE PREFERRED SHARES: Convertible preferred A stock, $0.00001 par value – Zero and 6,630,000 shares authorized as of June 30, 2022 and December 31, 2021, respectively. As of June 30, 2022 all issued an..." |
|
| 05/11/2022 |
8-K
| Quarterly results |
|
|